The anti-proliferative effect of HDAC inhibition in breast and prostate carcinoma cells reported here (Figure 1) is a common feature of HDAC1/2 inhibition [38] that has been observed preclinically in other tumor types [29, 39], as well as in breast cancer patients treated with vorinostat [40]. Here, HDAC1 is linked to breast cancer.